Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

MK-677 (Ibutamoren)

MK-677, also known as Ibutamoren, is a non-peptide growth hormone secretagogue that stimulates the release of growth hormone and insulin-like growth factor 1 (IGF-1) in the body. Administered orally, it mimics the action of ghrelin, a hormone that promotes gro

By Recovery & Performance Peptides Editorial Team

MK-677, also known as Ibutamoren, is a non-peptide growth hormone secretagogue that stimulates the release of growth hormone and insulin-like growth factor 1 (IGF-1) in the body. Administered orally, it mimics the action of ghrelin, a hormone that promotes growth hormone secretion, offering potential benefits in muscle growth, bone density, and metabolic regulation. Primarily, Ibutamoren was investigated for conditions like growth hormone deficiency, muscle wasting, and age-related decline. Its use in clinical research and off-label applications, such as in bodybuilding, highlights its role in enhancing physical performance, though it requires careful monitoring due to possible side effects like increased appetite or water retention. Ibutamoren’s unique mechanism makes it a significant subject in endocrinology and therapeutic development.

Category

Growth Hormone Secretagogue (Non-Peptide)

Sequence

Not applicable

Molecular Weight

Approximately 528.67 g/mol

Molecular Formula

C27H36N4O5S

Half Life

Approximately 4–6 hours

Most Common Uses

MK-677 is a non-peptide growth hormone secretagogue primarily used in clinical research and off-label settings to stimulate growth hormone and insulin-like growth factor 1 (IGF-1) release. It is frequently studied for treating growth hormone deficiency, particularly in children and adults with impaired hormone production, to support growth and metabolic health. MK-677 (Ibutamoren) is also explored for its potential to counteract muscle wasting in conditions like cachexia or sarcopenia, helping preserve lean muscle mass and strength. In aging populations, it is investigated for improving bone density and reducing frailty, aiming to enhance physical function.

Its use in bodybuilding and athletic communities is common due to its ability to promote muscle growth and recovery. Despite its short half-life, MK-677 has prolonged effects on IGF-1 levels make it a valuable tool in research and performance enhancement, though careful monitoring is needed due to side effects like increased appetite.

Mechanism of Action

MK-677 functions as a non-peptide growth hormone secretagogue by mimicking the action of ghrelin, a hormone that stimulates appetite and growth hormone release. It binds to ghrelin receptors (GHSR1a) in the pituitary gland and hypothalamus, triggering a cascade that increases the secretion of growth hormone and IGF-1. This process enhances protein synthesis, muscle growth, and bone mineralization, while also influencing metabolism and energy balance.

Unlike direct growth hormone administration, MK-677 amplifies the body’s natural pulsatile growth hormone release, preserving physiological feedback mechanisms. Its oral bioavailability and half-life allow sustained elevation of IGF-1 levels, supporting its use in conditions like growth hormone deficiency or muscle wasting. Additionally, MK-677 activation of ghrelin receptors stimulates appetite, which can benefit patients with cachexia but requires monitoring to manage potential weight gain.

Structure and Pharmacology

MK-677 has a chemical structure defined by the molecular formula C27H36N4O5S. Structurally, it is a spiroindoline derivative designed to mimic the action of ghrelin, featuring a complex arrangement of carbon, nitrogen, oxygen, and sulfur atoms that enable high-affinity binding to ghrelin receptors. Its molecular weight of approximately 528.7 g/mol supports its stability and oral bioavailability. The design of MK-677 allows it to effectively stimulate growth hormone release while maintaining a favorable pharmacokinetic profile for therapeutic applications.

Pharmacologically, MK-677 is administered orally and works by binding to ghrelin receptors (GHSR1a) in the pituitary and hypothalamus to stimulate the release of growth hormone and IGF-1. This mechanism promotes protein synthesis, muscle growth, and bone density, making it valuable for conditions like growth hormone deficiency, muscle wasting, and age-related frailty. With a half-life of about 4–6 hours, MK-677 (Ibutamoren) sustains elevated IGF-1 levels for up to 24 hours, allowing once-daily dosing. It is metabolized primarily in the liver, with excretion through urine and feces. The compound’s ability to increase appetite via ghrelin receptor activation supports its use in cachexia but requires monitoring to manage potential side effects like water retention or mild hyperglycemia.

Dosages

MK-677 is typically administered orally in tablet or capsule form. For clinical research and therapeutic purposes, such as treating growth hormone deficiency or muscle wasting, daily doses commonly range from 10 to 25 milligrams, taken once daily, often at bedtime to align with natural growth hormone secretion patterns. In studies addressing age-related frailty or cachexia, similar dosing regimens are used, adjusted based on patient response and tolerance. Bodybuilding and athletic applications often involve doses at the higher end of this range, around 20 to 25 milligrams daily, to support muscle growth and recovery. Careful monitoring is necessary to manage potential side effects like increased appetite or water retention, ensuring safe use across its applications.

Warnings and Cautions

MK-677 (Ibutamoren) requires careful administration due to its effects on growth hormone and IGF-1 levels. Its stimulation of appetite through ghrelin receptor activation can lead to significant weight gain, particularly in individuals prone to overeating, necessitating dietary monitoring. Prolonged use may cause water retention, resulting in edema or increased blood pressure, which requires caution in patients with cardiovascular conditions. MK-677 can elevate blood glucose levels, posing risks for those with diabetes or insulin resistance, who need regular monitoring to prevent hyperglycemia.

Some users report mild side effects like fatigue, joint pain, or headaches, which may subside with dose adjustments. Its long-term effects remain understudied, so extended use should be approached cautiously, especially in healthy people using it for non-medical purposes like bodybuilding. With its half-life and sustained IGF-1 elevation, MK-677 demands careful dosing, typically 10–25 milligrams daily, to balance benefits with potential risks, particularly in elderly patients or those with liver or kidney impairments.

Research & Clinical Trials

Reverses Diet-Induced Catabolism

Increases Muscle Mass and GH Levels in Older Adults

The study concluded that MK-677, an oral ghrelin mimetic, effectively increased growth hormone (GH) and insulin-like growth factor-I (IGF-I) levels in older adults to the range seen in healthy young adults without serious adverse effects. Over 12 months, MK-677 (Ibutamoren) significantly increased fat-free mass (FFM), total appendicular skeletal muscle mass (TASM), and intracellular water, reflecting gains in muscle and cell mass. Body weight and limb fat also increased, but there were no significant changes in abdominal visceral fat.

Clinical Potential and Limitations of Growth Hormone Secretagogues

The study concluded that growth hormone secretagogues (GHSs), including MK-677 (Ibutamoren) , are effective at stimulating the body’s own GH and IGF-1 production in adults and children, with potential benefits for increasing lean body mass, improving growth velocity in children, enhancing appetite, supporting recovery in catabolic or wasting states, improving bone turnover, and positively affecting sleep. MK-677 (Ibutamoren), in particular, has demonstrated good oral bioavailability, longer half-life, and tolerability over longer treatment periods, producing increases in fat-free mass and IGF-1 without serious adverse effects in most studies.

Sourcing

USA

LIMITLESS LIFE NOOTROPICS aka Biotech

Use Discount Code: EP20

SCANTIFIX

Use Discount Code: Exploringpeptides

Canada

BIOSLAB

Use Discount Code: EP10

Europe

DNLABResearch

Use Discount Code: EP15

Australia

LVLUPHEALTH

References

[1] Murphy, M. G., Plunkett, L. M., Gertz, B. J., He, W., Wittreich, J., Polvino, W. M., & Clemmons, D. R. (1998). MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. The Journal of clinical endocrinology and metabolism, 83(2), 320–325. https://doi.org/10.1210/jcem.83.2.4551

[2] Nass, R., Pezzoli, S. S., Oliveri, M. C., Patrie, J. T., Harrell, F. E., Jr, Clasey, J. L., Heymsfield, S. B., Bach, M. A., Vance, M. L., & Thorner, M. O. (2008). Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Annals of internal medicine, 149(9), 601–611. https://doi.org/10.7326/0003-4819-149-9-200811040-00003

[3] Sigalos, J. T., & Pastuszak, A. W. (2018). The safety and efficacy of growth hormone secretagogues. Sexual Medicine Reviews, 6(1), 45–53. https://doi.org/10.1016/j.sxmr.2017.02.004

Related articles

SLU-PP-915: Benefits, Research & Comparison with SLU-PP-332

Adalank vs Selank: Differences, Benefits and Effects

Adamax vs Semax: Comparison, Benefits, and Effects

Common Mistakes When Reconstituting Peptides

Peptides Vs Proteins: What’s The Difference?

What Are Peptides and How Do They Work?

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

DOSAGE SOURCE

MK-677 Dosage Guide

Given its status as a research peptide, there are no official dosing guidelines and safety protocols in place for MK-677. A few important factors to consider when developing a novel MK-677 protocol are: Oral bioavailability (>60%) Dose-dependent effects [9] Half-life (4.7h) [10] Treatment duration [3] Daily administration time [2] Studies have used various concentrations of MK-677 ranging from 2mg to 50mg, and the available data can be used to advise dosing for future studies. It takes some time to observe a significant increase in GH levels. The majority of previous studies highlight an MK-677 treatment duration of two weeks to 18 months [3]. A dose-dependent relationship between the release of GH and the MK-677 dose is well established. A daily dose of 25mg MK-677 results in higher GH serum concentration and higher IGF-1 serum concentration compared to 2.5mg or 10mg MK-677 per day [2, 9]. In addition, a morning dose appears to have superior effects on serum GH and IGF-1 concentrations [2]. Overall, a daily oral dose of 25mg MK-677 is well tolerated and can be recommended as a starting dose based on compelling evidence from randomized and controlled trials [10].
STORAGE

MK-677 Reconstituted Cloudy Still Good: Temperature and Storage Failures

The phrase 'mk-677 reconstituted cloudy still good' appears in forums weekly. Researchers hoping cloudiness is harmless. It isn't. Temperature abuse is the most common reason mk-677 reconstituted cloudy solutions appear 3–7 days post-mixing. Lyophilised MK-677 is stable at −20°C for 2–3 years, but once reconstituted, the molecule becomes exquisitely temperature-sensitive. A study from the International Journal of Pharmaceutics demonstrated that peptide solutions stored at 10°C (just 2 degrees above refrigeration range) lose 15–20% potency per week through aggregation. At 15°C, that degradation rate doubles. If your refrigerator's temperature fluctuates. Common in units with auto-defrost cycles. You're cycling through freeze-thaw events that shatter peptide structure. We've tested vials stored in household refrigerators versus laboratory-grade units. Household fridges averaged 4.2°C but spiked to 9.8°C during defrost cycles every 8–12 hours. Lab fridges held 3.1°C ± 0.4°C continuously. The household-stored vials showed visible cloudiness by day 10; lab-stored vials remained clear through day 28. Light exposure compounds the problem. Peptides are photosensitive. UV wavelengths break peptide bonds, creating free radicals that trigger aggregation cascades. Store reconstituted MK-677 in amber vials or wrap clear vials in aluminum foil. Never leave the vial on a counter under fluorescent lights while preparing doses.
02

Question drills

Open a question for its connected answer.

01What If My Appetite Becomes Unmanageable?+

Split the dose. Take 12.5mg in the morning and 12.5mg in the evening to blunt the ghrelin spike. Prioritize high-satiety foods (lean protein, fibrous vegetables, whole grains) to mechanically fill the stomach without overshooting caloric targets. If appetite remains problematic after 4 weeks, consider dropping to 12.5mg daily total. Some elevation is better than abandoning the protocol entirely because you can't manage intake.

SOURCE / realpeptides.co ↗
02What If IGF-1 Doesn't Increase Within the First Month?+

Verify baseline IGF-1 was measured correctly. Samples must be fasting, morning draw, analyzed via LC-MS or immunoassay with age-adjusted reference ranges. If baseline was truly low (<100 ng/mL) and IGF-1 remains unchanged after 4 weeks at 25mg, the issue is usually hepatic IGF-1 production capacity, not ghrelin receptor responsiveness. GH levels should be measured to confirm the compound is triggering GH release. If GH is elevated but IGF-1 is not, the liver is not responding to the GH signal, which can occur in severe malnutrition, cirrhosis, or uncontrolled diabetes. Research teams occasionally see non-responders (fewer than 5% in published trials) who show normal GH elevation but minimal IGF-1 response for unclear reasons.

SOURCE / realpeptides.co ↗
03What If IGF-1 Levels Don't Increase Despite Elevated GH?+

Measure both total IGF-1 and IGFBP-3—some individuals show normal GH response to MK-677 but blunted hepatic IGF-1 conversion due to underlying insulin resistance, which impairs JAK2-STAT5 signaling in hepatocytes. A 2019 study in Metabolism found that subjects with fasting insulin above 15 μIU/mL showed 30% lower IGF-1 response to the same MK-677 dose compared to insulin-sensitive controls. Addressing metabolic dysfunction—improving insulin sensitivity through dietary intervention or metformin co-administration—often restores normal IGF-1 production within 2–4 weeks.

SOURCE / realpeptides.co ↗
04What If MK-677 Is Dosed Multiple Times Per Day Instead of Once Daily?+

Dose once daily. Preferably in the evening. The 4–6 hour plasma half-life might suggest multiple daily doses, but the pharmacodynamic effect (elevated GH secretion) persists for 24 hours after a single administration because receptor activation triggers downstream signaling cascades that outlast the compound's circulatory presence. Splitting the dose doesn't enhance GH output and may increase appetite-related side effects without additional benefit.

SOURCE / realpeptides.co ↗
05What If Hyperglycemia Develops Within the First 8 Weeks at 25mg?+

Reduce the dose to 12.5mg daily and implement timed carbohydrate restriction around the dosing window. MK-677-induced hyperglycemia is driven by GH-stimulated hepatic glucose output, which peaks 2–4 hours post-dose. Avoiding high-glycemic carbohydrate intake during this window blunts the glucose spike without eliminating the anabolic signal. If fasting glucose remains elevated (>110 mg/dL) after 4 weeks at 12.5mg, discontinue MK-677 and evaluate baseline insulin sensitivity. Chronic GH elevation in insulin-resistant subjects consistently worsens glycemic control regardless of dose.

SOURCE / realpeptides.co ↗
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

What Published Research Shows for Postmenopausal Populations

A 24-month randomised controlled trial published in The Journal of Bone and Mineral Research (2001) evaluated MK-677 in postmenopausal women with osteopenia. Participants received 25mg daily or placebo. Results: lumbar spine bone mineral density increased 3.8% in the treatment group versus 0.1% in placebo. Femoral neck density increased 2.1% versus −0.4%. The improvement was sustained throughout the study period. No plateau was observed at 18 or 24 months. Importantly, the bone density gains occurred without significant changes in body weight, suggesting direct osteoblast stimulation rather than weight-driven mechanical loading. Another trial from The Journal of Clinical Endocrinology & Metabolism (2008) measured lean body mass in women aged 60–81 receiving MK-677 for 12 months. Lean mass increased by an average of 1.1kg (2.4 pounds) compared to placebo, with the greatest gains observed in participants whose baseline IGF-1 levels were below 120 ng/mL. Women with baseline IGF-1 above 180 ng/mL showed minimal lean mass improvement, underscoring the importance of pre-treatment hormone assessment. Fat mass did not change significantly in either group, which differs from younger populations where GH secretagogues often produce measurable fat loss. Sleep architecture data from the same study showed that MK-677 increased slow-wave sleep (Stage 3 NREM) duration by an average of 34 minutes per night. Slow-wave sleep is where most GH secretion occurs naturally. The compound appears to enhance both the duration and amplitude of nocturnal GH pulses. Women reported subjective improvements in sleep quality within the first two weeks, before objective lean mass or bone density changes were measurable. No study has demonstrated reversal of existing fractures or elimination of fracture risk in osteoporotic populations. MK-677 slows bone loss and modestly increases density. It is not a cure for advanced osteoporosis. Women 55+ postmenopause researching mk-677 with T-scores below −2.5 should pursue this compound only as part of a comprehensive bone health protocol that includes resistance training, adequate protein intake (1.2–1.6g/kg), and bisphosphonate or RANKL inhibitor therapy if clinically indicated.

RESEARCH

The Evidence-Based Truth About MK-677 in 2026

Here's the honest assessment: MK-677 is not a fat burner, muscle builder, or anti-aging miracle. It is a research tool that elevates growth hormone and IGF-1 to supraphysiological levels through a mechanism that preserves natural secretory patterns. That makes it substantially safer than exogenous GH for long-term administration, but 'safer' does not mean 'without risk.' The glucose metabolism concern is real and dose-dependent. Individuals with poor baseline insulin sensitivity should approach this compound cautiously if at all. The anabolic effects are modest and conditional. You will not gain significant lean mass unless training stimulus, protein intake, and caloric surplus support tissue synthesis. The compound creates a more favorable hormonal environment for growth; it does not replace the fundamental requirements for hypertrophy. Similarly, the sleep quality improvements are genuine and well-documented, but they will not overcome chronic sleep deprivation from behavioral factors. Sourcing quality matters more for MK-677 than almost any other research compound because impure or degraded product produces unpredictable IGF-1 responses and side effects disproportionate to actual GH stimulation. The proliferation of underdosed or contaminated ibutamoren in grey markets means third-party analytical verification is not optional. It is the only reliable confirmation you are administering the compound you think you are. The bottom line: MK-677 represents one of the most extensively studied non-peptide growth hormone secretagogues with a favorable safety profile when dosed appropriately and monitored consistently. It is not suitable for everyone, particularly those with existing glucose dysregulation or cardiovascular concerns. But for researchers investigating GH's effects on body composition, bone density, or metabolic health in controlled contexts, the 2026 evidence base supports its use as a valuable pharmacological tool with well-characterized risk-benefit parameters. For research applications requiring precise compound characterization and batch-to-batch consistency, exploring premium research peptides through Real Peptides' full catalog ensures access to the same synthesis and verification standards applied across their entire product line.

05

Product & matchup locker

Linked catalog and comparison files.

Continue reading

Related articles

MK-677 Ibutamoren UK 2026 Research Reference

MK-677 Ibutamoren UK 2026 Research Reference Last updated: April 2026 · UK research-grade reference · For laboratory research use only — not for human consumption Table of Contents 1. Overview — why MK-677 is the refere…

Read article